ImageneBio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
ImageneBio, Inc. (IMA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $13.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-03-10
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-12-31 was $0.00.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2023-09-30 was $0.00.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $13.00K.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $100.00K, a 91.67% decline from fiscal 2022.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.20M, a 36.84% decline from fiscal 2021.
- ImageneBio, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $1.90M, a 6233.33% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $13.00K 10-K · filed 2026-03-10 | ||||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $100.00K 10-K · filed 2025-03-06 | ||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $100.00K 10-Q · filed 2024-11-07 | $59.30K 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-08 | ||||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $0.00 derived: sum of 2 quarters · filed 2024-03-12 | $300.00K derived: sum of 3 quarters · filed 2024-03-12 | $1.20M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $300.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.20M 10-Q · filed 2023-11-09 | $2.40M derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.20M 10-Q · filed 2023-08-10 | $2.40M derived: sum of 3 quarters · filed 2023-08-10 | $2.50M derived: sum of 4 quarters · filed 2023-08-10 | |||
| 2022-03-31 | $900.00K 10-Q · filed 2023-05-15 | $2.10M derived: sum of 2 quarters · filed 2023-05-15 | $2.20M derived: sum of 3 quarters · filed 2023-05-15 | $2.30M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $1.30M derived: sum of 2 quarters · filed 2023-03-14 | $1.40M derived: sum of 3 quarters · filed 2023-03-14 | $1.90M 10-K · filed 2023-03-14 | |||
| 2021-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $200.00K derived: sum of 2 quarters · filed 2022-11-07 | $700.00K 10-Q · filed 2022-11-07 | $717.00K derived: sum of 4 quarters · filed 2022-11-07 | |||
| 2021-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $600.00K 10-Q · filed 2022-08-11 | $562.00K 10-Q · filed 2021-08-12 | $617.00K derived: sum of 3 quarters · filed 2022-08-11 | $617.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $500.00K 10-Q · filed 2022-05-12 | $478.00K 10-Q · filed 2021-05-13 | $517.00K derived: sum of 2 quarters · filed 2022-05-12 | $517.00K derived: sum of 3 quarters · filed 2022-05-12 | $517.00K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $17.00K derived: sum of 2 quarters · filed 2022-03-17 | $17.00K derived: sum of 3 quarters · filed 2022-03-17 | $30.00K 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 derived: sum of 2 quarters · filed 2021-11-10 | $13.00K 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $13.00K 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $13.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |